Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates

International Journal of Antimicrobial Agents

Volumn 35, Issue 1, 2010, Pages 76-79

  Moon, Dong Chan ^a   Seol, Sung Yong ^a   Gurung, Mamata ^a   Jin, Jong Sook ^a   Choi, Chul Hee ^a   Kim, Jungmin ^a   Lee, Yoo Chul ^a   Cho, Dong Taek ^a   Lee, Je Chul ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

DNA gyrase; Efflux pump; Fluoroquinolone; Mutation; Topoisomerase IV

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DNA TOPOISOMERASE IV; GATIFLOXACIN; GEMIFLOXACIN; NORFLOXACIN; OFLOXACIN; PROTEIN PARC; PROTEIN PARE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; ESCHERICHIA COLI; GENE MUTATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SOUTH KOREA; TEACHING HOSPITAL;

AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; POINT MUTATION; REPUBLIC OF KOREA;

EID: 70849098222     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.08.003     Document Type: Article

References (15)

1. Tavío M.M., Vila J., Ruiz J., Ruiz J., Martín-Sánchez A.M., and Jiménez de Anta M.T. Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli isolates. J Antimicrob Chemother 44 (1999) 735-742
2. Cavaco L.M., Frimodt-Møller N., Hasman H., Guardabassi L., Nielsen L., and Aarestrup F.M. Prevalence of quinolone resistance mechanisms and associations to minimum inhibitory concentrations in quinolone-resistant Escherichia coli isolated from humans and swine in Denmark. Microb Drug Resist 14 (2008) 163-169
3. Vila J., Ruiz J., Marco F., Barcelo A., Goñi P., Giralt E., et al. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother 38 (1994) 2477-2479
4. Bachoual R., Tankovic J., and Soussy C.J. Analysis of the mutations involved in fluoroquinolone resistance of in vivo and in vitro mutants of Escherichia coli. Microb Drug Resist 4 (1998) 271-276
5. Hopkins K.L., Davies R.H., and Threlfall E.J. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. Int J Antimicrob Agents 25 (2005) 358-373
6. Sorlozano A., Gutierrez J., Jimenez A., de Dios Luna J., and Martínez J.L. Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-β-lactamase-producing Escherichia coli isolates. J Clin Microbiol 45 (2007) 2740-2742
7. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M7-A7.Wayne, PA: CLSI; 2006.
8. Tamang M.D., Seol S.Y., Oh J.Y., Kang H.Y., Lee J.C., Lee Y.C., et al. Plasmid-mediated quinolone resistance determinants qnrA, qnrB, and qnrS among clinical isolates of Enterobacteriaceae in a Korean hospital. Antimicrob Agents Chemother 52 (2008) 4159-4162
9. Park C.H., Robicsek A., Jacoby G.A., Sahm D., and Hooper D.C. Prevalence in the United States of aac(6′)-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother 50 (2006) 3953-3955
10. Vila J., Ruiz J., Goñi P., Marcos A., and Jimenez de Anta T. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 39 (1995) 1201-1203
11. Yang H., Chen S., White D.G., Zhao S., McDermott P., Walker R., et al. Characterization of multiple-antimicrobial-resistant Escherichia coli isolates from diseased chickens and swine in China. J Clin Microbiol 42 (2004) 3483-3489
12. Sáenz Y., Ruiz J., Zarazaga M., Teixidó M., Torres C., and Vila J. Effect of the efflux pump inhibitor Phe-Arg-β-naphthylamide on the MIC values of the quinolones, tetracycline and chloramphenicol, in Escherichia coli isolates of different origin. J Antimicrob Chemother 53 (2004) 544-545
13. Sáenz Y., Zarazaga M., Briñas L., Ruiz-Larrea F., and Torres C. Mutations in gyrA and parC genes in nalidixic acid-resistant Escherichia coli strains from food products, humans and animals. J Antimicrob Chemother 51 (2003) 1001-1005
14. Cambau E., Bordon F., Collatz E., and Gutmann L. Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid. Antimicrob Agents Chemother 37 (1993) 1247-1252
15. Hardy C.D., and Cozzarelli N.R. Alteration of Escherichia coli topoisomerase IV to novobiocin resistance. Antimicrob Agents Chemother 47 (2003) 941-947